Sentences with phrase «treatment study results»
New York, NY About Blog Latest prostate cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for prostatic carcinoma.
https://blog.feedspot.com/
New York, NY About Blog Latest colorectal cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for colon cancer.
New York, NY About Blog Latest colorectal cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for colon cancer.
New York, NY About Blog Latest prostate cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for prostatic carcinoma.
New York, NY About Blog Latest colorectal cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for colon cancer.
About Site - Latest colorectal cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for colon cancer.
About Site - Latest prostate cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for prostatic carcinoma.
New York, NY About Blog Latest prostate cancer news, articles, research and treatment study results for oncology nurses to assist in delivering updated patient care for prostatic carcinoma.
Not exact matches
As a result, «we are building on these findings to refine existing treatments to boost feelings of being safe and supported in order to improve coping with traumatic memories,» said Dr. Anke Karl, one of the authors, wrote of the study.
Once the final results of those studies are analyzed this spring — and the early evidence has been encouraging — the challenge will be to get FDA approval for human trials and then bring the treatment to market.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«Based on the results from these Phase 3 studies, the combination of bictegravir and FTC / TAF could represent an important advance in triple - therapy treatment for a broad range of HIV patients, and we look forward to submitting regulatory applications in the U.S. and EU this year.»
Join us for key insights from the CoMMpass Study, including results that patients and caregivers may find helpful for treatment decisions.
Living Goods told us at that time that the results from the RCT were not going to be reliable due to spillover of the intervention into control locations and incorrect matching of the treatment area and the treatment survey area — issues that reduce the statistical power of the study.1
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
Potential subjects were accepted into the study if they had none of the following conditions: severe or symptomatic cardiac disease or hypertension; history of bleeding disorders; chronic history of gastric, intestinal, liver, pancreatic, or renal disease; any portion of the stomach or the intestine removed (other than an appendectomy); history of intestinal obstruction, malabsorption, or use of antacid drugs; cancer (active or use of medications for a history of cancer treatment within the past 5 y); history of chronic alcoholism; a convulsive disorder; or abnormal results in screening blood or urine samples.
Although these results sound promising, Mathew cautions that more studies on larger groups of people need to be done before he can recommend capsaicin as a definite treatment for cluster headaches.
In a new study commissioned by The March of Dimes Foundation and published in Fertility and Sterility, researchers from The Hastings Center and Yale Fertility Center examined the practical circumstances of infertility treatment in the US that influence patients and their doctors to make treatment choices that too frequently result in multiple births.
As a result, Dr. Meehan argues that «the term mild traumatic brain injury should not be used interchangeably with concussion,» as suggested by the authors of a 2010 Canadian study, 2 which found that how a brain injury was labeled made a difference when it came to treatment, and suggested that, to encourage full reporting of head injuries in sports and to allow adequate management and recovery time, MTBI be used in its place.
Sleep experts reviewed 52 studies of various behavioral treatments that address bedtime problems and night wakings among infants and toddlers; 49 of the studies showed positive results.
While there is some evidence to suggest that helmeted children recognize that they are somehow different, a 2008 study on the quality of life of children who had undergone helmet therapy discovered that 96 % of patients and their families were satisfied with treatment results.
Given the results of a a new study reported in the British medical journal, The Lancet4 that children and young adults scanned multiple times by CT have a small increased risk of leukemia and brain tumors in the decade following their first scan, parents should make sure a CT scan is really necessary in treatment of their child after head injury.
Again, there was some evidence that the treatment effect may be partly due to bias; sensitivity analysis including only those studies assessed as being at low risk of bias for allocation concealment showed that results still favoured the intervention group although the treatment effect was less pronounced in the studies at lower risk of bias (Analysis 1.8).
A new study says more than one in five emergency visits to an «in - network» hospital results in treatment by an «out - of - network» physician.
«These results take us one step closer to developing highly effective lucid dream induction techniques that will allow us to study the many potential benefits of lucid dreaming, such as treatment for nightmares and improvement of physical skills and abilities through rehearsal in the lucid dream environment,» Dr Aspy says.
Kadouri analyzed rats» gut microbes after a treatment of predatory bacteria, reporting the results in a study published March 6 in Scientific Reports.
One way out of this dilemma, Daviglus notes, is to design a study in which patients suffering from hypertension get treatment, and doctors analyze the results based on how well the patients» blood pressure was controlled.
«There is certainly much left to be studied — including how pregnancy and fertility treatments may affect mortality later in life — but our results highlight the fact that a history of infertility is indeed related to a woman's life long health, and opens a potential opportunity for screening and / or preventative management for infertile women for both women's health care providers and the general practitioner.»
The results of this study suggest that TAK1 should be further explored as a target for obesity treatment.
In three randomized trials, treatment of chronic low back pain with radiofrequency denervation, a procedure that can be performed with different techniques including the application of an electric current to the pain - conducting nerve, resulted in either no improvement or no clinically important improvement in chronic low back pain, according to a study published by JAMA.
She elaborates, «In the study, these patients underwent imaging with a PSMA PET scan and had treatment based on the results of the scan findings.
With the results of the current study in hand, Snyder has brokered a deal between that company and the National Institute on Drug Abuse (NIDA) for NIDA to test CGP3466B as a treatment for cocaine addiction.
Results of the study, which ultimately included 146 men of whom 99 received SRT, show an overall treatment response after SRT of 72 percent.
«This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer,» stated Anthony Victor D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology, Brigham and Women's Hospital and senior author of the study.
«A significant body of research has resulted in a shift from thinking of placebos as just «dummy» treatments to recognizing that placebo effects encompass numerous aspects of the health care experience and are central to medicine and patient care,» said the article's coauthor Ted Kaptchuk, Director of the Program in Placebo Studies at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School.
Emmett points out, «The results of the study show that PSMA PET is more predictive of a treatment response than PSA level, surgical margins or seminal vesical involvement.»
While researchers await the results of the Parkinson's studies, they look beyond to nicotine treatments for other disorders as well.
In addition to suggesting that creatine could slow the progression of HD, these results also imply that neuroimaging may provide a useful biomarker of disease modification in studies of other potential treatments.
But some studies indicate shortening treatment courses would leave patients vulnerable to a resurgence of infection or, in some cases, potentially result in selective growth of resistance organisms.
The benefit of antibiotic treatment of ASB following screening is also an open issue, as the results of the over 40 - year - old studies can not be applied to the current healthcare situation.
She says the results merit a larger study to discover the best timing and combination of treatments.
Results of the study indicate that eating more high - pesticide residue fruits and vegetables (for example, strawberries and raw spinach) was associated with a lower probability of pregnancy and live birth following infertility treatment.
Feusner, who also is a professor of psychiatry at the David Geffen School of Medicine at UCLA, said if the study's results are replicated, OCD treatment could someday start with a brain scan.
«For the study, we chose a decision analysis design because we could use a mathematical model to simulate the outcomes and costs of each treatment path based on results and costs that have already been published in the literature,» Dr. Dodwell explained.
«Our results provide evidence for clinicians to consider HRT as compared with CRT as a preferred radiation treatment in men with intermediate - risk prostate cancer and at low risk of other complications,» stated Trevor Royce, MD, MPH, radiation oncologist at Brigham and Women's Hospital and first author of the study.
Ubogu says the results of these proof - of - concept studies strongly point to CD11b as a treatment target for peripheral nerve inflammation.
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.
Rondina says the study's results do not immediately change diagnosis or treatment options for age - related cognitive impairments, but it will be interesting to see the long - term implications of these results, as we continue to learn how our brains change as we age.
Sheba Meymandi, a professor of medicine at the University of California Los Angeles, and the director of the Center of Excellence for the Diagnosis and Treatment of Chagas Disease who was not involved in the study, had a different take on the results.
Managing the microbiome instead of pummeling it with antibiotics has produced impressive results in chicken and mice studies, pointing the way not just to future human treatments but also to a healthier food supply.